This is a summary of the European public assessment report (EPAR) for Zytiga. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zytiga. For practical information about using Zytiga, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Zytiga is indicated with prednisone or prednisolone for: * the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated * the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
Therapeutic Area (MeSH)
ATC Code
L02BX03
ATC Item
N/A
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| abiraterone acetate | N/A | abiraterone acetate |
EMA Name
Zytiga
Medicine Name
Zytiga
Aliases
N/ANo risk management plan link.
